Medicinal Cannabis

Microcap Cannabis Stock BOD has two major near term catalysts…

Wise-Owl Jun 26, 2023

BOD Science (ASX:BOD) has shifted gears from slowly growing revenue, in favour of going for a big blue sky approach to delivering shareholder outcomes. With two near term catalysts on the horizon, could this be the time for BOD?

BOD: Clinical trials set to begin on chemist-available, cannabis insomnia treatment

Wise-Owl Mar 24, 2023

There have not been any CBD products approved yet for OTC sale in pharmacies - yet. However our sub-$10M capped cannabis Investment BOD Science (ASX:BOD) is keen to be first to enter the national market.

Tiny Medical Cannabis Stock BOD Has Started Two Clinical Trials - We are Hoping for a Re-rate on Results

Wise-Owl May 20, 2022

BOD has just began two clinical trials, we are hoping for a re-rate on results of these trials. BOD dosed the first patients for the following trials in the last month for Insomnia (Phase 2b) and Long-COVID (Open label).

What We DO and DON’T like about the proposed CPH Merger

Next Investors Jun 17, 2021

Today Creso Pharma (ASX: CPH | OTC: COPHF) announced its plans to merge with a Canadian listed psychedelics company called Red Light Holland.

CPH to expand US footprint after USOTC listing

Finfeed Archived Jun 11, 2021

The US OTC listing gives Creso Pharma Ltd (ASX: CPH) greater exposure to a deeper capital market as well as greater access and liquidity for North American investors. Further to this, it provide additional opportunities to attract institutional and retail investors and for CPH to expand its investor base in the US.

NTI Begins Autism Clinical Trials for Unique Cannabis Strain

Catalyst Hunter Archived May 05, 2021

Neurotech International Ltd (ASX: NTI) has begun its first clinical trials on children aged between 5 and 17 years with Autism Spectrum Disorder (ASD) for its unique cannabis strain.

Revenues up 237%: Creso Pharma delivers strong quarter ahead of OTC listing

Finfeed Archived Apr 30, 2021

There were several highlights to come out of the quarterly report released by Creso Pharma (ASX: CPH) today. CPH is enjoying a sustained run this year with revenues up 237% in the lead up to its US listing, which is expected to occur in the coming weeks.

Bod Australia outlines strong revenue growth

Finfeed Archived Apr 22, 2021

Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited (ASX: BDA) has provided its shareholders an update for the Q3FY2021 quarter, ended 31 March 2021.

Halucenex agreement to give CPH another leg up in psychedelics

Finfeed Archived Mar 31, 2021

Creso Pharma’s (ASX: CPH) pending acquisition of Halucenex Life Sciences should prove to be an astute move, with Halucenex continuing to rapidly move towards its goal of developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets.

$18M will help CPH progress near-term revenue initiatives

Finfeed Archived Mar 26, 2021

Creso Pharma (ASX: CPH) has received firm commitments to raise $18M, a sum that significantly shores up its balance sheet. CPH will use the funds to progress a number of value accretive opportunities including Phase II and Phase III clinical trial initiatives with target acquisition company Halucenex Life Sciences Inc.

CPH to list on the OTC as it expands North American footprint

Finfeed Archived Mar 23, 2021

Creso Pharma (ASX: CPH) today announced it is listing on the OTC market in the USA. Listing on the OTC is expected to unlock significant shareholder value and provides CPH with access to one of the largest investment markets in the world at nominal cost.

Revenue generating BDA sets its sights on US market

Finfeed Archived Mar 17, 2021

Bod Australia (ASX: BDA) is a cannabis centric healthcare company, with well-branded premium, proven and trusted products within two distinct verticals: Medical Cannabis and CBD and Hemp Consumer products.

NTI secures strategic Cultivation partnership to grow and maintain its medical cannabis

Finfeed Archived Mar 09, 2021

Neurotech International Limited (ASX: NTI) has announced a strategic cultivation partnership with CannaPacific Limited to grow and maintain genetic stock and assist in the development of elite varietal strains through their exclusive licencing agreement.

Page 1 of 9 next >